MINDBREEZE
25.2.2021 13:07:05 CET | Business Wire | Press release
Mindbreeze and Austinat & Haarhaus are teaming up to take on intelligent information provision. The communications technology specialist helps customers streamline their digital workplaces and optimize workflows.
“Understanding information is crucially important today – especially when the goal is to optimize and transform business processes. Partnering with Mindbreeze generates new opportunities for our customers, since Mindbreeze InSpire offers them a new and deeper view of their enterprise data,” explains Mike Auer, Managing Director of Austinat & Haarhaus.
Mindbreeze InSpire delivers business-relevant data speedily and seamlessly. The insight engine merges traditional search technologies with cutting-edge technological advances from the field of artificial intelligence. The system analyzes and interprets enterprise data from connected data sources, delivering actionable insights and concrete answers to questions. More than 2,000 of the world’s largest companies are already leveraging this AI-powered insight engine to pinpoint relevant information in the right context and understand correlations quickly.
“Recent months have illustrated how having access to essential data can be a real competitive differentiator,” notes Daniel Fallmann, founder and CEO of Mindbreeze. “Our new partner Austinat & Haarhaus specializes in efficient corporate communications solutions. Now this service offering is augmented with Mindbreeze InSpire. We’re looking forward to the projects we’ll be working on together.”
About Austinat & Haarhaus
Austinat & Haarhaus GmbH is an owner-managed company that has provided ICT services for 30 years. The company offers high-quality conventional telecommunications and telephone system design solutions, along with a wide range of other services. Austinat & Haarhaus GmbH is also a certified provider in the field of security technology. This includes intercom and control systems, as well as video and radio technology. Austinat & Haarhaus offers long-standing expertise as a leading partner for network operators in the area of telecommunication solutions and hardware manufacturers. In recent years, Austinat & Haarhaus GmbH has responded to its customers’ growing demand for digitalization by establishing a dedicated in-house IoT and programming department. A modern on-site workshop, highly qualified technicians, and a competent in-house service team round off the 360-degree support Austinat & Haarhaus provides to its customers.
About Mindbreeze
Mindbreeze is a leading international provider of appliances and cloud services for enterprise search, applied artificial intelligence, and knowledge management. Mindbreeze’s global network of partners enables the company to serve customers anywhere in the world across all time zones.
You can find more information at www.mindbreeze.com or follow us on LinkedIn and Twitter @Mindbreeze.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005549/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release
Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli
Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release
With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release
− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b
Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release
Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c
EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release
Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom